PDI and Transgenomic Partner to Commercialize Molecular Diagnostic Test

(Parsippany, NJ, USA) and Transgenomic (Omaha, NE, USA) have entered into an agreement to commercialize CardioPredict, a broad-based genetic assay that identifies a patient’s specific genes, which influence the effectiveness and safety of many commonly used cardiovascular drugs. The collaboration was formed to influence the fast-growing pharmacogenetic testing segment that has exhibited significant expansion over the last several years, particularly in the cardiovascular therapeutic area.

The CardioPredict personalized medicine test is well positioned as a comprehensive assay that captures a specific set of genes known to influence each individual patient's ability to metabolize commonly used cardiovascular drugs.

Under the terms of the collaboration agreement, PDI will be responsible for all US-based marketing and promotion of CardioPredict, while Transgenomic will be responsible for processing CardioPredict in its Clinical Laboratory Improvement Amendments (CLIA) lab and all customer support. Both parties will bear the cost of their respective expenses and will split profit on a formula basis. In addition, PDI will provide Transgenomic with funding support, principally to mitigate working capital requirements. Other financial terms of the collaboration were not disclosed.

Nancy Lurker, CEO of PDI, Inc. said, “CardioPredict provides an advanced personalized cardiovascular solution to patients who are taking one or more commonly prescribed cardiovascular drugs in helping them and their physicians better assess how they individually metabolize and respond to these drugs. Relative to higher-risk cardiovascular patients being treated within several critical drug classes: Antiarrythmic, Anticoagulants, Anti-thrombotics, Statins and Beta-blockers, it is generally acknowledged that there are important genetic variants that significantly influence drug absorption, activation or metabolism/elimination and should be considered when determining drug selection, dosing and monitoring. CardioPredict represents a new personalized tool, with proprietary, patent pending features, to help assure that high-risk cardiovascular patients get the appropriate drug regimen and doses for their unique personal genetic profile. We believe the clinical value to patients is significant. There is a large market, a well-defined patient population and a clearly identified physician base treating these patients that should allow for a very efficient use of PDI’s broad base of commercialization capabilities.”

PDI is a health care commercialization company providing integrated multichannel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients.

Transgenomic, Inc. is a biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases. The company has three complementary business divisions: Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools, which provide specialized diagnostic tests, contract research services for drug development, and equipment, reagents, and other consumables for clinical and research applications in molecular testing and cytogenetics.

Related Links:
PDI Inc.
Transgenomic